Total : 282 View more »
New Book Takes Wyeth (now Pfizer) to Task for Opposition to Bio-Identical Hormone Replacement. Lane Lenard PhD. and Dr. Jonathan V. Wright’s new book, Stay Young & Sexy with Bio-Identical Hormone Replacement, slams Wyeth and the FDA for hypocrisy regarding stance on Premarin® and Provera®.
POTOMAC, Md., Nov. 24 /PRNewswire/ -- In addition to family, friends and health, cancer survivor Diane Wisneski has added Philadelphia jurors to her Thanksgiving gratitude list. "They heard the facts and made the just choice.
http://www.prnewswire.com/news-releases/maryland-woman-thankful-for-wyeth-verdicts-72963342.html
Acquisition expands world’s biggest drugmaker into a diversified health care giant, but the merger is expected to result in nearly 20,000 job cuts.
http://www.manufacturing.net/News-Pfizer-Completes-68B-Acquisition-Of-Wyeth-101509.aspx
R&D will be conducted at five main sites and nine specialized units around the world, compared with 20 R&D sites.
http://www.industryweek.com/articles/pfizer_slashes_research_staff_after_wyeth_deal_20375.aspx
Total : 117 View more »
POTOMAC, Md., Nov 24, 2009 /PRNewswire via COMTEX/ --
In addition to family, friends and health, cancer survivor Diane Wisneski has added Philadelphia jurors to her Thanksgiving gratitude list.
"They heard the facts and made the just choice. I am so thankful to them," she said of Monday's verdicts totaling $103 million in damages against Wyeth Pharmaceuticals.
Wisneski is among 12,000 women nationwide who have sued Wyeth and Pfizer pharmaceuticals, makers of the hormone therapy drugs Premarin and Prempro. Wisneski and the other victims of hormone therapy have alleged in lawsuits that Wyeth and Pfizer inappropriately promoted spurious benefits of the drugs, failed to do studies to establish that the drug was safe for long term use, and down played the risks to patients and their doctors. Wisneski's case has yet to come to trial.
"When I was first diagnosed, I had one grandchild. I prayed I would live to see his first birthday. Today I have five, and am thankful every day for the chance to see them grow up. Other women have not been so lucky," Wisneski said.
Her attorney, Robert K. Jenner, of Baltimore, said the verdicts reflected, "Outrage by average Americans against deception, lies and misdirection."
Breast cancer survivors are continuing to win the war against Wyeth and Pfizer. Of the last 12 jury verdicts, 10 have awarded compensation to plaintiffs.
"When the facts are laid on the table, jurors find Wyeth and Prempro responsible for causing an epidemic of breast cancer," he said. "Wyeth lawyers actually tell jurors, 'Hormone therapy does not cause cancer.' This goes against everything the National Cancer Institute and the National Institutes of Health have announced to be true. It's no wonder that juries routinely levy punitive damage verdicts against these companies."
Jenner, with Janet, Jenner & Suggs, is co-counsel for Connie Barton, of Peoria, Ill. The jury's $75 million punitive damage verdict against Wyeth was announced on Monday. The firm has represented Barton since March 2004 when the Peoria woman contacted Jenner, a pharmaceutical liability lawyer. The case was tried by their co-counsel, Zoe Littlepage and Rainey Booth.
Comments from Barton, along with plaintiff, Donna Kendall, who was awarded $28 million, along with other information about the litigation, can be viewed at http://myadvocates.com/prescription-drugsmedications/double-trouble-for-pfizer
Kendall is represented by Philadelphia attorney Tobias Millrood.
Sales of Prempro have fallen dramatically since 2002 when a large federal health study, the Women's Health Initiative, was halted when researchers confirmed a link between Prempro and breast cancer.
About Janet, Jenner & Suggs
The law firm of Janet, Jenner & Suggs, LLC is a nationally recognized law firm dedicated to representing victims of defective medical devices, prescription drugs and medical malpractice. Each of the firm's principals is named in The Best Lawyers in America(R) and Super Lawyers(R). The firm has offices in Baltimore, Maryland and Columbia, South Carolina. The firm accepts clients and referrals from patients and attorneys throughout the country.
Released by Janet, Jenner & Suggs
For more information contact Teresa Kelly, 512-328-4276
SOURCE Janet, Jenner & Suggs
http://www.medlawlegalteam.com/index.html
Tags: breast cancer cancer doctors drugs epidemic family federal health law maryland medical pharmaceuticals sales south carolina trial woman women
Companies: Wyeth (WYE)
Dublin, Nov 13, 2009 (M2 PRESSWIRE via COMTEX) --
Research and Markets (http://www.researchandmarkets.com/research/36b054/wyeth_2009_fortune) has announced the addition of the "Wyeth 2009 Fortune Global 500 Snapshot Company Profile" company profile to their offering.
This report provides in-depth company profiles for Wyeth as ranked in the 2009 Fortune Global 500 list. All data is gathered from primary source. Reports are available in easily accessible PDF format and data is consistently presented. Data is regularly tracked and enhanced to ensure data on these high profile companies is accurate and current. This report is an indispensable tool for investors wanting to gather the relevant facts on the major companies in Asia Pacific. The author concentrates on a small number of high profile companies using tested and trusted research and editorial methodologies.
Countries Covered
United States
Key Topics Covered:
This report provides the following corporate data where available:-
- Company Name
- Company Variant Name
- Address
- Primary Telephone Number
- Primary Fax Number
- Website
- SIC Codes
- Date of Establishment
- Stock Exchange and Ticker
- Competitors
- Activities Description
- Board of Directors
- Senior Management and Key Decision Makers
- Executive Biographies
- Selected Financial Data covering 8 Years (Sales, PBT, PAT, Shareholders' Equity, Total Assets, EPS and Dividends)
- Analyst Coverage
- Trade Names
- Locations
For more information visit http://www.researchandmarkets.com/research/36b054/wyeth_2009_fortune
CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (from USA) Fax: +353 1 481 1716 (rest of the world) e-mail: press@researchandmarkets.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Tags: asia dividends email e-mail eps equity executive investment opinion research sales trade united states web
Companies: Wyeth (WYE)
Nov 11, 2009 (PRWeb.com via COMTEX) --
On November 2, 2009, the United States Court of Appeals for the Eighth Circuit issued its long-awaited decision in Scroggin v. Wyeth (Case No. 08-2555). The decision gives the green light for federal trials on Wyeth's and Pfizer's hormone therapy (http://www.hkllp.com/hormone-replacement-therapy/) drugs. In affirming judgment on a jury verdict of compensatory damages, the federal appellate court rejected the defendants' claims that plaintiffs like Donna Scroggin cannot prove that hormone therapy caused their breast cancer. It also found that the statute of limitations began to run from the announcement of the startling results of the Women's Health Initiative study ("WHI") in July, 2002. Erik Walker of Hissey Kientz, LLP (http://www.hkllp.com/) in Austin, Texas handled the appeal for Ms. Scroggin, writing her briefs and arguing to the court. Walker lauded the court's decision. "The opinion reveals the court became well-versed in the complex issues presented in this litigation. The decision finally forecloses Wyeth's cynical claim that even though its drugs caused countless women to develop breast cancer, Wyeth can never be held accountable because no woman can prove that her particular cancer was caused by the drugs."
Donna Scroggin took Wyeth's Premarin (estrogen) and Pfizer-subsidiary, Upjohn's Provera (progestin). She then took Wyeth's Prempro, which combined estrogen and progestin (E+P) into a single pill. After 11 years using the products, Ms. Scroggin developed hormone-dependent cancer in both of her breasts, compelling a double mastectomy and debilitating treatments. A jury awarded Ms. Scroggin $2.75 million in compensatory damages. The jury also found that Wyeth and Upjohn's negligence reflected reckless disregard to women's health, awarding nearly $20 million in punitive damages against Wyeth and nearly $8 million against Upjohn. The district court rejected Wyeth's attacks on the compensatory award but set aside the punitive awards. The Eighth Circuit found there was sufficient documentary evidence of reckless disregard to warrant a new trial on punitive damages against Wyeth.
Jim Morris, who tried the case, looks forward to the new trial: "We appreciate the opportunity to once again present evidence of Wyeth's conscious disregard for the rights and welfare of Ms. Scroggin to a jury. Most juries find Wyeth's conduct to be reprehensible and we expect Arkansans to be equally incensed yet again." Walker said the decision is great news for breast cancer (http://www.hkllp.com/hormone-replacement-therapy/hrt-and-breast-cancer/) victims throughout the country. "Studies show that E+P has caused over a quarter of a million women in this country to develop breast cancer. Only a fraction of those women have filed suit. This decision ensures that these women may continue their pursuit for justice."
About Hissey Kientz, LLP Hissey Kientz, LLP represents individuals who contracted mesothelioma (http://www.hkllp.com/mesothelioma-and-asbestos/), lung cancer or other diseases as a result of asbestos exposure, and those injured by Yaz or Yasmin birth control pills (http://www.hkllp.com/yaz-and-yasmin/), a fentanyl or Duragesic overdose, acute phosphate nephropathy as a result of a Fleet Phospho-soda bowel cleansing products, Digitek, Zicam, the Composix Kugel mesh patch, gadolinium MRI contrast dyes, Reglan, FELA railroad injury lawsuits, Raptiva, the Ortho Evra patch, Fen-Phen or "herbal Fen-Phen" products containing ephedra or ma huang, as well as other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP (www.hkllp.com) or call toll-free at (866) 275-4454.
###
Read the full story at http://www.prweb.com/releases/hormone-therapy/hrt-lawsuit/prweb3188274.htm.
PRWeb.com
Tags: breast cancer cancer drugs federal health massachusetts products railroad soda texas trial woman women writing
Companies: Wyeth (WYE)
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) --
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the third quarter and nine months ended September 30, 2009.
Financial Results
Net loss for the third quarter of 2009 was $13.0 million or $0.41, basic and diluted, per share, compared to $12.2 million or $0.40, basic and diluted, per share in the third quarter of 2008. Net loss for the nine months ended September 30, 2009 was $30.0 million or $0.97, basic and diluted, per share, compared to a net loss of $30.1 million or $1.00, basic and diluted, per share for the first nine months of 2008.
Revenues for the third quarter of 2009 totaled $5.4 million, compared to $17.5 million for the same period of 2008, reflecting a decrease in reimbursement revenue from Wyeth (NYSE: WYE) for RELISTOR(R) research and development under the recently terminated 2005 collaboration between Wyeth and Progenics. For the first nine months of 2009, Progenics reported revenues of $31.8 million compared to $60.8 million for the comparable period of 2008. Revenues for nine months also reflect a decrease in reimbursement and milestone revenue from Wyeth, offset by recognition in the first quarter of a $15.0 million upfront payment received in 2008 from Ono Pharmaceutical Co., Ltd. (OSE-TYO: 4528), Progenics' collaborator for subcutaneous RELISTOR in Japan.
Expenses for the third quarter of 2009 were $18.6 million, compared to $31.2 million for the same period in the previous year. For the nine months ended September 30, 2009, expenses totaled $63.5 million, compared to $95.9 million for the same period of 2008.
Progenics ended the quarter with cash, cash equivalents and marketable securities of $106.8 million, a reduction of $10.7 million from $117.5 million at June 30, 2009.
The decreases in expenses for the third quarter and nine months ended September 30, 2009 compared to 2008 were attributable primarily to decreases of $10.3 million and $29.9 million, respectively, in research and development expenses. The overall decreases, which reflect increases in PSMA-related clinical activities, resulted primarily from:
-- Reduced RELISTOR development expenses following completion of Progenics-conducted clinical trials and other development work; and
-- Reduced manufacturing activities for PRO 140 clinical trials.
Global net sales of RELISTOR for the third quarter of 2009 were $3.3 million, as compared to $3.2 million in sales for the previous quarter and $0.8 million for the third quarter of 2008 when RELISTOR had only been partially launched by Wyeth. Of the current period's global net sales, U.S. net sales comprised $1.8 million, as compared with $2.0 million in the previous quarter.
"During the third quarter, we worked diligently to regain worldwide rights to RELISTOR, the only approved drug for opioid-induced constipation, and our announcement just after the closing of this quarter was a significant event," said Paul J. Maddon, Founder, Chief Executive Officer and Chief Science Officer of Progenics Pharmaceuticals. "We are excited about the future of the RELISTOR franchise, including our plans to submit an sNDA by early 2011 for approval of subcutaneous RELISTOR for the treatment of opioid-induced constipation in the broader chronic-pain market and to take immediate responsibility for development of oral RELISTOR. We believe that RELISTOR is just beginning to realize its potential in the opioid-induced constipation marketplace."
Third Quarter Highlights
-- Applications for a new RELISTOR pre-filled syringe delivery system were submitted to the U.S. Food and Drug Administration and the European Union European Medicines Agency. Pre-filled syringes are designed to ease preparation and administration for patients and caregivers and, if approved, could be available to advanced-illness patients in the U.S. and Europe as early as the first half of 2010.
-- Mark R. Baker, formerly Executive Vice President -- Corporate, was appointed President and a member of the Board of Directors. He continues to report to Dr. Maddon. In his new role, Mr. Baker oversees business and commercial development, strategic planning, investor relations, corporate communications, finance and accounting, operations and legal affairs.
October Highlights
-- Progenics and Wyeth terminated their 2005 collaboration, and Progenics is regaining all worldwide rights to the RELISTOR franchise. Progenics will assume full control of future development and commercialization of subcutaneous RELISTOR after a transition period, and is taking over clinical and non-clinical development of the oral form of the drug. Wyeth has agreed to pay Progenics a total of $10.0 million in installments through January 2011, and to provide support by continuing manufacturing, marketing, sales, distribution, ongoing clinical studies and regulatory activities for subcutaneous RELISTOR over the transitional period. Wyeth is also committing up to $14.5 million of funding for development of RELISTOR in a multi-dose pen delivery system for the chronic-pain patient population and for pediatric clinical trials. Progenics' out-license of subcutaneous RELISTOR to Ono Pharmaceutical in Japan is not affected by the Wyeth collaboration termination.
-- Positive data from a phase 2 study of methylnaltrexone treatment during rehabilitation following orthopedic procedures was presented at the annual meeting of the American Academy of Physical Medicine and Rehabilitation. The hypothesis-generating study was conducted by Progenics in 33 patients and served to evaluate methylnaltrexone in a new patient setting. Significantly more patients on study drug experienced laxation within two and four hours compared to those on placebo (39% versus 7%, [p<0.05] and 33% versus 0%, [p<0.05], respectively). In addition, the median time to laxation in the methylnaltrexone group was nearly one day earlier than the placebo group. Incidences of adverse events were comparable between the two treatment groups, and no serious adverse events were reported. Data from this study will support the safety portion of the chronic-pain sNDA planned for FDA submission by early 2011.
PROGENICS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except net loss per share)
For the Three Months Ended For the Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
Revenues:
Research and development $ 4,431 $ 16,015 $ 29,206 $ 54,896
Royalty income 509 44 976 86
Research grants and contract 404 1,377 1,421 5,689
Other revenues 75 61 189 172
Total revenues 5,419 17,497 31,792 60,843
Expenses:
Research and development 11,345 21,478 39,055 68,191
License fees - research and development 136 305 961 1,788
General and administrative 5,844 8,265 19,758 22,530
Royalty expense 51 5 98 9
Depreciation and amortization 1,207 1,166 3,633 3,427
Total expenses 18,583 31,219 63,505 95,945
Operating loss (13,164) (13,722) (31,713) (35,102)
Other income:
Interest income 123 1,502 1,457 5,028
Gain on sale of marketable securities - - 237 -
Gain on disposal of fixed assets 27 - 46 -
Total other income 150 1,502 1,740 5,028
Net loss $ (13,014) $ (12,220) $ (29,973) $ (30,074)
Net loss per share; basic and diluted $ (0.41) $ (0.40) $ (0.97) $ (1.00)
Weighted average shares outstanding; basic and diluted 31,428 30,323 31,060 30,048
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands)
September 30, 2009 December 31, 2008
Cash, cash equivalents and marketable securities $ 106,756 $ 141,374
Accounts receivable 697 1,337
Fixed assets, net 8,080 11,071
Other assets 1,513 4,051
Total assets $ 117,046 $ 157,833
Liabilities $ 12,547 $ 38,464
Stockholders' equity 104,499 119,369
Total liabilities and stockholders' equity $ 117,046 $ 157,833
About Subcutaneous RELISTOR
RELISTOR subcutaneous injection is approved in the United States for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. The use of RELISTOR beyond four months has not been studied. The drug is also approved for use in over 30 countries worldwide, including the European Union, Canada, Australia and Brazil. Applications in additional countries are pending.
Important Safety Information for RELISTOR
-- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
-- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician.
-- Use of RELISTOR has not been studied in patients with peritoneal catheters.
-- The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs. 9.8%), flatulence (13.3% vs. 5.7%), nausea (11.5% vs. 4.9%), dizziness (7.3% vs. 2.4%), diarrhea (5.5% vs. 2.4%), and hyperhidrosis (6.7% vs. 6.5%).
-- RELISTOR full Prescribing Information for the U.S. is available at www.relistor.com.
About Subcutaneous RELISTOR for OIC in the Chronic-pain Setting
In May 2009, Progenics and Wyeth reported a positive outcome from a 470-patient, phase 3 efficacy clinical trial in patients with chronic, non-cancer pain. This study showed statistically significant improvements in the occurrence of bowel movements with the use of RELISTOR. Adverse events observed in this study were similar to those seen in prior studies. Enrollment was also recently completed for phase 3 safety study of over 1,000 patients, with results expected by the end of 2010. Results from these two studies are expected to be included in an sNDA submission by early 2011. If FDA approval of the application is granted, Progenics plans to launch subcutaneous RELISTOR in a multi-dose pen for the chronic-pain OIC market thereafter.
(PGNX-F)
About Progenics
Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, virology and oncology. Progenics is developing RELISTOR(R) (methylnaltrexone bromide) for the treatment of opioid-induced side effects. RELISTOR is currently approved in over 30 countries, including the U.S., E.U. member countries, Canada, Australia and Brazil; marketing applications are pending elsewhere throughout the world. Progenics is pursuing strategic alternatives for RELISTOR, including licensing, collaboration, strategic alliances and U.S. commercialization or co-promotion, following termination of its 2005 collaboration with Wyeth Pharmaceuticals, which is continuing manufacturing, sales, marketing, and certain development and regulatory activities for RELISTOR during the transition. Ono Pharmaceutical Co., Ltd. has an exclusive license from Progenics for development and commercialization of subcutaneous RELISTOR in Japan. In the area of virology, Progenics is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody which binds to co-receptor CCR5 to inhibit human immunodeficiency virus (HIV) infection. PRO 140 is currently in phase 2 clinical testing. The Company's hepatitis C virus discovery program seeks to identify novel inhibitors of HCV entry. In oncology, the Company is conducting a phase 1 clinical trial of a human monoclonal antibody-drug conjugate (ADC) for the treatment of prostate cancer--a selectively targeted chemotherapeutic antibody directed against prostate-specific membrane antigen. PSMA is a protein found on the surface of prostate cancer cells as well as in blood vessels supplying other solid tumors. Progenics is also conducting phase 1 clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.
PROGENICS DISCLOSURE NOTICE: This document contains statements that do not relate strictly to historical fact, any of which may be forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When we use the words "anticipates," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, do not gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development might reduce the commercial potential of our products; we, our collaborators or others might identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not originating from subsequent testing or other activities by us, governmental regulators, other entities or organizations or otherwise, and whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, declining sales or other adverse events.
We are also subject to risks and uncertainties associated with the actions of our corporate, academic and other collaborators and government regulatory agencies, including risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; the risk that we may not be able to enter into favorable collaboration or other relationships or that existing or future relationships may not proceed as planned; the risk that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity, or that our rights to in-licensed intellectual property may be terminated for our failure to satisfy performance milestones; the risk of difficulties in, and regulatory compliance relating to, manufacturing products; and the uncertainty of our future profitability.
Risks and uncertainties also include general economic conditions, including interest and currency exchange-rate fluctuations and the availability of capital; changes in generally accepted accounting principles; the impact of legislation and regulatory compliance; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; trade buying patterns; the competitive climate of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission. In particular, we cannot assure you that RELISTOR will be commercially successful or be approved in the future in other formulations, indications or jurisdictions, or that any of our other programs will result in a commercial product.
We do not have a policy of updating or revising forward-looking statements and we assume no obligation to update any statements as a result of new information or future events or developments. It should not be assumed that our silence over time means that actual events are bearing out as expressed or implied in forward-looking statements.
Editors Note:
For more information about Progenics Pharmaceuticals, Inc., please visit www.progenics.com.
For more information about RELISTOR, please visit www.RELISTOR.com.
SOURCE: Progenics Pharmaceuticals, Inc.
Investors: Progenics Pharmaceuticals, Inc. Richard W. Krawiec, Ph.D., 914-789-2814 Vice President, Corporate Affairs krawiecr@progenics.com or Dory A. Kurowski, 914-789-2818 Associate Director, Corporate Affairs dkurowski@progenics.com or Media: WeissComm Partners Aline Schimmel, 312-646-6295
Tags: academic accounting annual report australia brazil business canada cancer clinical commercial communications contract corporate currency editors equity europe executive fda finance financial results government grants hiv infection japan legal legislation manufacturing market marketing medical medicine nasdaq new_york note nyse patent pharmaceuticals policy population president products property prostate cancer research research and development revenue sales securities trade trial unions
Companies: Progenics Pharmaceuticals, Inc. (PGNX)
Total : 2,159 View more »
MUMBAI: Pharma major Wyeth on Friday said its net profit rose by 9.79 per cent to Rs 29.15 crore for the quarter ended June 30, 2009 over the same period last year. The company had a net profit of Rs 26.
Wyeth Consumer Healthcare | Wyeth Special Offers | Contact us | Site Map | © 2009 Wyeth Consumer Healthcare Privacy · Terms & Conditions This site is intended only for residents of the United States
Advertising sales, marketing, creative, online and print services for direct clients and advertising agencies.
http://www.bandt.com.au/view_company.asp?pubcatid=2005&companyid=19214
... ... ...COLLEGEVILLE Pa. July 27 /- Wye... ...,Wyeth,Reports,Publication,of,Phase,3,Data,for,Bazedoxifene/Conjugated,Estrogens,,an,Investigational,Compound,Being,Studied,for,the,Treatment,of,Menopausal,Symptoms,medicine,advanced medical technology,medical laboratory technology,medical device
Total : 2,210,000 View more »
Wyeth, formerly known as American Home Products (AHP), was one of the largest pharmaceutical companies in the world. The company is based in Madison, New Jersey, USA.
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and ...
http://www.wyeth.com/?rid=/wyeth_html/home/shared/footer/sitemap.html
Wyeth pharmaceutical company brings health care products, medicines and vaccines that aim to improve lives and deliver value to customers.
http://www.wyeth.com/?rid=/wyeth_html/home/articles/homepage_article_emerald.html
Wyeth makes Premarin, which contains estrogen, and Prempro, a combination of estrogen and progestin. Pharmacia and Upjohn made Provera, a progestin hormone sometimes combined with ...
http://www.nytimes.com/2009/11/24/business/24wyeth.html?ref=health
Leading the way to a healthier world. By working at Wyeth, you can help others to live longer, more fulfilling lives while realizing other important professional objectives.
“I would say this is an excellent opportunity to learn about the importance of tape and the technology behind the making of a first class product. Networking with your peers will allow you to return home with ideas to improve your operations.” - Gord Hanna, Canadian National
It’s a great pleasure to speak with people who are on the front lines of aging about a subject that has very much been on my mind -- although having celebrated my 58th birthday recently, I’ve come to understand that I’m on the front lines of aging myself.
Session 3: High Throughput Bulk Process Development. Applications of high throughput methodologies, including robotics, for medium optimization and purification process development.
Bernard Poussot, Executive Vice-president of Wyeth and President of Wyeth Pharmaceuticals, joined the company in 1986 as Deputy General Manager of Wyeth France.